The bacterial enzyme carboxypeptidase G2 (CPG2) can be expressed both intracellularly (CPG2*) or tethered to the outer surface (stCPG2(Q)3) of mammalian cells, where it is able to activate mustard prodrugs for use in suicide gene therapy protocols. Here we compare the properties of CPG2 expressed in these two locations. CPG2 is active as a dimer, and one of the mutations required to block glycosylation of stCPG2(Q)3 destabilizes the dimers. Some of the mutations to this site partially correct the dimerization defect and recover a proportion of the activity. Surface tethering also recovers some enzyme activity, but through an unknown mechanism. The efficacy of CPG2 in these two locations is compared with the tumor cell lines A2780, SK-OV-3, and WiDr, which are sensitized to the prodrug 4-([2-chloroethyl][2-mesyloxyethyl]amino)benzoyl-L-glutamic acid (CMDA) by both CPG2* and stCPG2(Q)3 expression in suicide gene therapy protocols in vitro. We find that stCPG2(Q)3 is a more efficient mediator of CMDA-dependent cell killing than CPG2*. Lower levels of stCPG2(Q)3 activity are required to give cell killing that can only be achieved by higher levels of CPG2*. In bystander effect assays, low levels of stCPG2(Q)3 are required for efficient killing, whereas relatively high levels of CPG2* activity are required. Also, shorter exposures to prodrug are required for cell killing when stCPG2(Q)3 is expressed compared with when CPG2* is expressed. These data demonstrate that the location of the enzyme in the cell is more important than the enzyme activity as the determinant in mediating cytotoxicity.
A major problem with current therapies for cancer is the lack of specificity, resulting in harmful side effects to normal tissues, such as the gut lining and bone marrow. Much research is therefore focused on improving delivery of chemotherapeutic agents to cancer cells. Gene-directed enzyme prodrug therapy (GDEPT 1 ) and virally directed enzyme prodrug therapies 2 are suicide gene therapy approaches that aim to increase the delivery of toxic metabolites to solid tumors. In the first step, a gene encoding a foreign, prodrug-activating enzyme is delivered to tumor cells in such a fashion as to ensure its tumor-restricted expression. Subsequent systemic administration of an appropriate prodrug results in generation of toxic metabolites only at the tumor site and consequently tumor selective killing. A number of methods to ensure tumor-specific expression of the activating enzymes have been proposed, including injection of naked DNA, 3 targeted liposomes, 4 viruses, 5, 6 and transcriptional regulation. 5, [7] [8] [9] However, none of these delivery systems will target all of the tumor cells, and so a bystander effect is required. 2, 10, 11 This is defined as the ability of cells expressing the activating enzyme to kill nonexpressing, neighboring cells. Thus, even if gene transduction efficiencies are low, a substantial bystander effect will allow significant antitumoral activity. In animal models, the role of the bystander effect in suicide gene therapy has been established. 2, 10, 12, 13 Many enzyme/prodrug combinations for suicide gene therapy have been described. 9 We have focused on the use of the enzyme carboxypeptidase G2 (CPG2), from Pseudomonas strain RS16. CPG2 activates benzoic acid mustard prodrugs such as 4-([2-chloroethyl][2-mesyloxyethyl]amino)benzoyl-L-glutamic acid (CMDA) to release L-glutamic acid and the DNA alkylating drug 4-([2-chloroethyl][2-mesoxyethyl]amino)benzoic acid (Fig 1) , a potent cytotoxic agent.
14 CPG2 has a number of advantages over other enzyme/prodrug combinations. One is that the toxic drug is released directly from the prodrug, without requiring further modification by cellular enzymes, reducing the likelihood of induced drug resistance. Furthermore, mustard drugs are toxic to both cycling and noncycling cells, [15] [16] [17] a distinct advantage for chemotherapeutic agents. Another advantage of CPG2 is that the enzyme does not require any cosubstrates to activate the prodrug and therefore does not rely on cellular factors for activity.
The x-ray crystal structure of the protein reveals that CPG2 forms a homodimer, which is composed of a dumbbell-shaped structure, comprising two distinct catalytic domains separated by a dimer interface. 18 It is this dimeric form of the protein that is the active enzyme. 19 In bacteria, CPG2 normally resides in the periplasm; however, in mammalian cells, CPG2 is highly versatile and has been expressed within the cells or tethered to their outer surfaces. 20, 21 However, surface-tethered CPG2 (stCPG2) was inappropriately glycosylated on three asparagine residues (N222, N264, and N272), 22 resulting in a loss of activity, a proportion of which was restored by mutating these residues to glutamines to prevent glycosylation (referred to as stCPG2(Q)3).
Intracellularly expressed CPG2 (referred to as CPG2*) sensitized human colorectal adenocarcinoma cells (LS174T and WiDr) and human ovarian adenocarcinoma cells (A2780 and SK-OV-3) to CMDA and was also able to mediate a robust bystander effect. 20 In mixtures of expressing and nonexpressing cells, complete cell kill was observed when only 4 -12% of the population expressed CPG2*, depending upon the cell line used. CPG2* did not sensitize the human breast adenocarcinoma cell line MDA MB 361 to CMDA, because the prodrug did not enter the cytosol of these cells. 21 However, MDA MB 361 cells could be sensitized to CMDA by stCPG2(Q)3 expression, because the prodrug was activated outside the cells and the toxic metabolite was able to enter the cells to mediate both direct and bystander cell killing.
In this study, CPG2* and stCPG2(Q)3 enzymes are characterized further. The efficacy of these two enzymes is compared directly in cell lines that are sensitized to CMDA by CPG2* and stCPG2(Q)3, which was not possible previously because the MDA MB 361 cells were not sensitized to prodrug by intracellular enzyme expression. We show that mutations to N264 reduce dimer stability, which explains why enzyme activity is reduced. However, the process of surface tethering results in an unexpected recovery in enzyme activity. In cell-killing experiments, stCPG2(Q)3 was found to be more efficient than CPG2* at mediating CMDA-dependent cell death in a number of tumor cell types. Consequently, low levels of stCP2(Q)3 expression and high levels of CPG2* expression result in a similar sensitivity to CMDA and in similar bystander effects. Furthermore, even when the cells are exposed to CMDA for short time periods, stCPG2(Q)3-expressing cells are efficiently killed, whereas longer treatments are required for similar levels of cytotoxicity in CPG2*-expressing cells. Thus, surface tethering of CPG2 offers many advantages in suicide gene therapy that may be applicable to other enzyme/ prodrug systems.
MATERIALS AND METHODS

Generation of mutations
The plasmids pMCEFcpg2*, pMCEFcpg2(Q)3, and pMCEFstcpg2(Q)3, encoding, respectively, cytosolic CPG2*, cytosolic CPG2* bearing three asparagine to glutamine mutations, and stCPG2(Q)3 with the same three mutations have been described previously. 20, 21 A BsmFI recognition site was inserted downstream of the codon expressing CPG2 amino acid S274 in the mammalian expression plasmid pEFcpg2(Q)3 as follows. Two polymerase chain reaction fragments, generated using a primer recognizing the 5Ј end of the CPG2 gene and oligonucleotide 1, and a primer recognizing the 3Ј end of the CPG2 gene and oligonucleotide 2, were fused by mixing the fragments and by amplification using the flanking 5Ј and 3Ј primers. An internal SphI-SalI fragment from this fusion was used to replace the corresponding region in pEFcpg2*(Q)3, generating a plasmid in which the CPG2*(Q)3 coding sequence was interrupted by introduction of the BsmFI sequence GGGAC (shown in bold below). A further BsmFI recognition site was introduced into this plasmid using a similar strategy, but replacing oligonucleotides 1 and 2 with oligonucleotides 3 and 4. This generated a plasmid in which the CPG2* coding sequence is interrupted downstream of the codon encoding S274 with the BsmFI sequence GGGAC, and upstream of the codon encoding N264 with GTCCC (shown in bold below), the BsmFI sequence in the opposite orientation: Oligonucleotide 1, CGCCAAGGC-CGGCCAAGTCTCGGGGACAACATCATCCCCGCC; oligonucleotide 2, GGCGGGGATGATGTTGTCCCCGAGAC-TTGGCCGGCCTTGGCG; oligonucleotide 3, AAGAAACC-TGCGCTTCGTCCCCAATGGACCATCGCC; oligonucleotide 4, GGCGATGGTCCATTGGGGACGAAGCGCAGGT-TCTT;
The gene containing the two BsmFI sites was fused to the c-erbB2 signal peptide; the c-erbB2-CPG2(Q)3 fusion gene containing the two BsmFI sites was subcloned into pUC18, which has no BsmFI sites, under the transcriptional control of the lacZ promoter. After cutting with BsmFI, the large fragment of this plasmid was ligated to sets of hybridized oligonucleotides that replaced the missing section and permitted SPOONER, MARTIN, FRIEDLOS, ET AL: LOCALIZATION OF ACTIVATING ENZYME alteration of specific sites. After transformation, CPG2 genes encoding altered amino acids were identified by DNA sequencing; activity of the encoded enzymes was screened by examining the ability of conditioned growth medium to degrade methotrexate (MTX), a good CPG2 substrate. 19 Altered genes were further subcloned to generate plasmids encoding CPG2* and stCPG2 variants under elongation factor 1-␣ transcriptional control for transient expression in mammalian cells.
Generation of cell lines constitutively expressing stCPG2(Q)3
All mammalian cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf sera (FCS). For this study, the human colorectal carcinoma cell line WiDr 23 and the human ovarian carcinoma cell lines SK-OV-3 24 and A2780 25 were separately transfected with the plasmid pMCEFstcpg2(Q)3; 21 G418-resistant colonies were selected by limiting dilution. Detergent-soluble extracts were incubated with MTX, a good CPG2 substrate. The rate of change of absorbance at 320 nm was measured to identify those colonies able to degrade MTX and therefore likely to be expressing stCPG2(Q)3. Expression of stCPG2(Q)3 was confirmed by immunoblotting these detergent-soluble extracts using a rabbit polyclonal serum specific for CPG2. 20, 21 Cell lines constitutively expressing ␤-galactosidase (␤-gal) or CPG2* have been described previously. 20 Enzyme kinetic studies COS-7 cells were used for transient expression to provide detergent-soluble extracts containing large amounts of CPG2*, CPG2*(Q)3, and stCPG2(Q)3 enzymes for enzyme kinetic studies. Detergent-soluble cell extracts and enzyme kinetic analyses have been described previously. 20, 21 Levels of CPG2 protein in detergent-soluble extracts were determined by quantitative immunoprotein blotting using a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif) standardized with purified CPG2 expressed in insect cells. The kinetic parameters of the CPG2-derived proteins were measured, in all cases using 50 ng of CPG2* per assay and the equivalent amount of the internally expressed and cell surface-tethered variants. The specific activity of COS/CPG2* preparations containing 50 ng of CPG2* protein was assigned as 100%.
Kinetics of cell death and cytotoxicity assays
CMDA prodrug was synthesized as described previously. 26 To determine the exposure times of CMDA required for cytotoxicity of 50% of the populations, cell lines were plated at 3 ϫ 10 5 cells/well in 6-well tissue culture plates and allowed to grow to confluence. Tissue culture medium was replaced with 1 mL of DMEM/FCS containing 2 mM CMDA (for WiDr and SK-OV-3 cell lines) or 1 mM CMDA (for A2780 cell lines). These concentrations are not cytotoxic to control cell lines expressing ␤-gal. After varying times of exposure, cells were trypsinized and ϳ3% were replated. After an additional 4-day growth period, cell survival was determined by [ 3 H]-thymidine incorporation (0.4 Ci/mL, 6 hours).
For cytotoxicity assays, cells were grown to confluence and treated twice with identical doses of CMDA in DMEM/FCS, initially for 1 hour, immediately followed by an 18-hour treatment as described previously. 20 Doses were as follows: WiDr (W3 and W4) and SK-OV-3 (S5-S7) at 1000, 500, 250, 125, and 62.5 M CMDA; SK-OV-3 (S2.4 and S2.34) at 4000, 2000, 1000, 500, 250, 125, and 62.5 M CMDA; A2780 (A3 and A4) at 1000, 500, 250, 125, 100, 62.5, 50, 25, 12.5, and 6.25 M CMDA. Cells were trypsinized, and ϳ3% were replated and allowed to grow for an additional 4 days, when uptake of [ 3 H]-thymidine was used to infer survival. For bystander assays, mixtures of cells expressing stCPG2(Q)3 and cells of the same lineage expressing ␤-gal were treated with a single concentration of CMDA in the same two-stage treatment protocol as described previously, 20 using 2 mM CMDA for WiDr and SK-OV-3 cells and 1 mM CMDA for A2780 cells. Under these conditions, these concentrations of CMDA do not kill the bystander recipient cell lines when tested in the absence of stCPG2(Q)3-expressing cells.
RESULTS
Characterization of stCPG2
The initial aim of this study was to determine why the asparagine to glutamine mutations that blocked glycosylation reduced CPG2 enzyme activity. By examining the crystal structure of CPG2, we observed that all three amino acids lie within the dimerization domain of CPG2, suggesting that the loss of activity could be due to effects on dimer stability. To test this hypothesis, CPG2* was transiently expressed in COS cells, and the stability of the dimers was determined by nonreducing sodium dodecyl sulfate-polyacrylamide gel analysis. CPG2 dimers are highly stable, and in this gel system, the CPG2* dimer migrates with an apparent M r of ϳ80,000 (Fig 2A, lane 2) , although a proportion of the protein migrates as a monomer with an apparent M r of ϳ46,000 (Fig 2A, lane 2) . When the samples were heated before gel loading, no CPG2* dimers were observed under these conditions (Fig 2A, lane 12) . By contrast, dimers formed by CPG2* in which N222, N264, and N272 are all substituted with glutamines (CPG2*(Q)3) are unstable and migrate as monomers even when the sample is not heated (Fig 2A, lanes 3 and 13) .
Each position was tested independently. CPG2*(N222L) and CPG2*(N272L) both formed stable dimers in this gel system, whereas CPG2*(N264L) migrated as a monomer ( Fig 2B, lanes 2-4) , suggesting that N264 is a crucially important amino acid for maintaining dimer stability. These observations are consistent with the positions of these residues within the dimer interface. The side chains of N222 and N272 are at the surface of the interface, pointing away from the dimer core and into solution, so their mutation is unlikely to affect the dimer structure. However, the side chain of N264 is buried within the interface, forming interactions with the opposite monomer, providing a rationale for why mutations to this residue affect dimer stability.
It is surprising that the three glutamine for asparagine substitutions recovered enzyme activity, 21 as the glutamine side chain is considerably larger than that of asparagine and so may be sterically unfavorable. From the crystal structure, the N264Q mutation would be expected to cause some distortion of the dimer interface, so we tested whether substitution with amino acids with smaller side chains would result in improved dimer stability and enzyme activity. The glutamine at position 264 in CPG2*(Q)3 was therefore substituted with serine, threonine, or alanine, and dimer stability and enzyme activity were examined. Dimer stability is not improved by either the threonine (CPG2*(QTQ)) or alanine (CPG2*(QAQ)) substitutions, whereas the serine (CPG2*(QSQ)) substitution restores some of the dimers (Fig 2A, lane 4) . However, this restoration of dimer stability had complex effects on enzyme activity.
As we have shown, CPG2* has a K m of 7 M and catalytic activity close to that of bacterially produced protein. 20 This is defined as 100% activity, and we find that CPG2*(Q)3 has a K m that is similar to that of CPG2*, but significantly reduced catalytic activity (Table  1) . Despite having improved dimer stability compared with CPG2*(Q)3, CPG2*(QSQ) has a ϳ6-fold reduced affinity for its substrate but a ϳ2-fold improved catalytic activity (Table 1) . CPG2*(QTQ) also has improved catalytic activity, but a greatly reduced apparent affinity for substrate, and CPG2*(QAQ) was found to be practically inactive (Table 1) .
We investigated how these mutations affect stCPG2. As with CPG2*, the stCPG2(Q)3 proteins substituted for threonine (stCPG2(QTQ)) and alanine (stCPG2(QAQ) at position 264 do not form stable dimers, whereas weak dimers are seen with the serine substituted protein (stCPG2(QSQ)) (Fig 2A, lane 8) . Intriguingly, despite the lack of improvement in dimer stability with surface tethering of stCPG2, there is a substantial recovery of activity in the alanine-substituted protein. Whereas CPG2*(QAQ) was inactive, stCPG2(QAQ) had high enzyme activity (38% of CPG2*) and a K m for MTX of 69 M. In fact, the process of surface tethering overrides the effects of the N264 substitutions, as all four stCPG2 variants have K m values in the range of 45-69 M MTX and catalytic activities of 29 -40% of that of CPG2* (Table 1 ). Even the low K m (10.4 M MTX) of CPG2*(Q)3 is increased to 54 M MTX by the surfacetethering process (Table 1) .
Taken together, these data demonstrate that N264 substitutions have complex effects, affecting CPG2 dimer stability, reducing enzyme activity, and affecting substrate affinity when the protein is expressed in the cytosol. By contrast, surface tethering restores enzyme activity and affinity for substrate. stCPG2 sensitizes mammalian cells to CMDA We tested whether stCPG2 was more efficient than internally expressed CPG2 at directing prodrug-mediated cell killing in a variety of cells. As all of the enzyme activities of the surface-tethered proteins are similar, we chose one example, stCPG2(Q)3, for tumor cell studies. To conduct these experiments, WiDr (human colorectal adenocarcinoma), SK-OV-3, and A2780 (both human ovarian tumor lines) cells were engineered for stable expression of stCPG2(Q)3. The presence of stCPG2(Q)3 was verified by immunoprotein blotting (data not shown), and the levels of enzyme activity in these clones were determined using MTX as substrate (Table 2 ). For each cell line, two or three independently derived clones were examined. The SK-OV-3 clones expressing stCPG2(Q)3 protein express the lowest levels of CPG2 activity (0.016 -0.023 U/mg protein) followed by the A2780 clones (0.06 and 0.067 U/mg), with WiDr clones expressing the highest level of CPG2 activity (0.177 and 0.226 U/mg) ( Table 2 ).
All of these isolates are more sensitive than parental cells expressing ␤-gal to the prodrug CMDA. The A2780 clones are the most sensitive, with 50% inhibitory concentration (IC 50 ) values in the range of ϳ15-21 M CMDA; this is an increase in sensitivity of Ͼ100-fold compared with ␤-gal-expressing cells (IC 50 of 2150 M, Table 2 ). WiDr cells expressing stCPG2(Q)3 have IC 50 values in the range of 100 -150 M, which is between 22-and 32-fold more sensitive than the ␤-gal-expressing WiDr cells (IC 50 of Ͼ3200 M, Table 2 ). SK-OV-3 clones expressing stCPG2(Q)3 have IC 50 values of 200 -550 M, an increased sensitivity of 7-to 20-fold compared with ␤-gal-expressing controls (Table 2 ). These data show that all three cell lines can be sensitized to CMDA by expression of stCPG2(Q)3. However, the concentrations of enzyme activity were not found to be a determinant of susceptibility to CMDA. Thus, although the WiDr clones express ϳ3 times more enzyme activity than the A2780 clones, the A2780 clones are 5-10 times more sensitive to CMDA than the WiDr clones (Tables  1 and 2 ). Similarly, although WiDr clones express ϳ10 times more enzyme activity than the SK-OV-3 clones, the WiDr clones were only 1.5-5.5 times more sensitive to CMDA than the SK-OV-3 clones (Tables 1 and 2 ). This indicates that for each cell type, a threshold enzyme concentration is all that is required for complete cytotoxicity.
It is clear that the levels of CPG2 activity in these stCPG2(Q)3-expressing clones are consistently lower than we have obtained for CPG2*-expressing clones, and yet similar levels of susceptibility to CMDA are observed. For example, the A2780 clone expressing CPG2* from our previous study expressed 0.964 U/mg CPG2, 20 ϳ15 times more enzyme activity than the stCPG2(Q)3-expressing clones in this study (Table 2) , and yet the CPG2* clone had an IC 50 for CMDA of 23.2 M, similar to the 15-to 21-M values reported here for the stCPG2(Q)3 clones (Table 2) . Similarly, the WiDr clone expressing CPG2* contained 0.787 U/mg CPG2 enzyme activity, 20 ϳ3.5-4.5 times more CPG2 activity than the stCPG2(Q)3 clones (Table 2) , and yet its IC 50 of 277 M 20 was actually slightly higher than the IC 50 values reported here for the stCPG2(Q)3 expressers (100 -147 M). Finally, the SK-OV-3 clone expressing CPG2* contained 1.013 U/mg CPG2, 20 ϳ44 -63 times more enzyme activity than the stCPG2(Q)3 clones (Table 2), but its IC 50 for CMDA at 258 M fell within the range seen with the stCPG2(Q)3 clones (216 -544 M, Table 2 ).
These data indicate that stCPG2(Q)3 can sensitize a wide range of human tumor cells to CMDA more efficiently than CPG2*. To examine this directly, we isolated more CPG2*-expressing SK-OV-3 cell lines that were selected for lower levels of CPG2 enzyme activity. Two such isolates (S2.34, S2.4) were obtained that express 0.014 and 0.023 U/mg CPG2 enzyme activity, respectively. similar to the levels obtained with the stCPG2(Q)3-expressing clones of 0.016 and 0.023 U/mg (Table 2 ). These CPG2* clones proved to be rather resistant to CMDA, with IC 50 values of 3196 and 1289 M, respectively; these values were considerably higher than the values for the stCPG2(Q)3 expressers, which were all Ͻ600 M ( Table 2) . We conclude that these two proteins sensitize cells through different routes and that expression of stCPG2(Q)3 results in improved activation of CMDA compared with expression of CPG2*. Low concentrations of stCPG2(Q)3 enzyme activity give IC 50 values that are only achieved with higher levels of CPG2* and, when balanced for enzyme activity, stCPG2(Q)3 gives significantly lower IC 50 values than CPG2*.
We tested whether stCPG2 could mediate a bystander effect in these cells by coculturing known proportions of ␤-gal-and stCPG2(Q)3-expressing cells in the presence of CMDA and determining cell survival. In all cell types, stCPG2(Q)3 was able to mount a robust bystander effect ( Table 3 ). The best bystander effect is seen with WiDr cells, where Ͻ4% stCPG2(Q)3 expression causes 90% cytotoxicity. In the A2780 and SK-OV-3 cells, 90% cell kill is obtained when 11% and 15%, respectively, of the population express stCPG2(Q)3.
stCPG2(Q)3 activates CMDA more rapidly than CPG2* Our data show that stCPG2(Q)3 expression is a better activator of CMDA than is expression of CPG2*, presumably because stCPG2(Q)3 is on the outside of the cell and so has better access to the prodrug. To test this hypothesis, we performed time course experiments. Cells expressing stCPG2(Q)3 or CPG2* were exposed to one course of CMDA for different periods, and cell survival was determined as before. For these experiments, stCPG2(Q)3-or CPG2*-expressing cell lines were used that had similar IC 50 values. Thus, in these experiments, the cells expressing stCPG2(Q)3 contained significantly lower CPG2 enzyme activity than the CPG2*-expressing cells. With the WiDr cells, 50% of the cells expressing stCPG2(Q)3 (0.226 U/mg CPG2 activity, Table 2 ) were killed when exposed to CMDA for only 1.7 hours, whereas the cells expressing CPG2* (0.787 U/mg CPG2 activity 20 ) required 8 hours of exposure to obtain this level of cell kill (Fig 3, Table 4 ). Similarly, with SK-OV-3 cells, 50% cell death is achieved with a 10-hour exposure to prodrugs when the cells express stCPG2(Q)3 (0.023 U/mg), whereas 15 hours of exposure is required when CPG2* (1.013 U/mg 20 ) is expressed (Fig 3) . Similar effects were observed when bystander effect analyses were performed in which 20% of the cells express either stCPG2(Q)3 or CPG2*, with the remainder expressing ␤-gal. Under these conditions, with the A2780 clones, Ͻ30 minutes of exposure with the prodrug results in 50% cell death with both CPG2*-and stCPG2(Q)3-expressing clones; it is therefore impossible to detect significant differences in exposure times. In WiDr cells, 50% cell death is achieved within 3.4 hours when the CMDA activator is stCPG2(Q)3, whereas this level of cell death takes Ͼ11 hours when the activator is CPG2*. Similarly, with SK-OV-3 cells, 50% cell kill is achieved within 13.5 hours when the activator is stCPG2(Q)3 and within 27.5 hours when the activator is CPG2*.
DISCUSSION
The CPG2/CMDA enzyme/prodrug combination has been examined in two distinct GDEPT systems: entry of the prodrug into the cytosol for activation by CPG2* and activation at the cell surface by stCPG2(Q)3. We have also further characterized the enzymes. We note that levels of enzyme activity in the cell clones expressing stCPG2(Q)3 are consistently lower than levels of activity in clones expressing CPG2*. This is due in part to reduced enzyme activity caused by mutation of the asparagine at position 264, which is necessary to prevent N-linked glycosylation of this residue and consequent inactivation at the cell surface. 21 The x-ray crystal structure reveals that N264 lies deep within the dimer inter- *Mixtures of cells expressing stCPG2(Q)3 and cells expressing ␤-gal were treated with either 1 mM or 2 mM CMDA, and the proportion of activator cells required to kill 50%, 90%, or 100% of the cell population was determined. Cells expressing CPG2* or stCPG2(Q)3, and a mixture of 80% cells expressing ␤-gal and 20% cells expressing activating enzyme, were treated with 1 mM (A2780) or 2 mM (WiDr, SK-OV-3) CMDA, and the length of exposure required to kill 50% of the cell population was determined.
face of the CPG2 homodimer, 19 and we show that the glutamine substitution at this residue reduced homodimer stability. Our attempts to restore dimer stability by substituting amino acids other than glutamine at this position in the cytosolic CPG2 context met with limited success. Although one of the mutations, the serine substitution, gives some restoration of dimer stability and a concomitant doubling in enzyme activity, this was at a cost to substrate affinity, as there is a 6-fold increase in K m . The other mutations at this position do not restore dimer stability and one, the alanine substitution, is practically inactive.
The surface-tethering process appears to overcome many of the detrimental effects induced by the N264 substitutions. Thus, the K m values for cytosolic CPG2* proteins in which N222 and N272 (the other two glycosylated amino acids) are substituted for glutamine, but position 264 is substituted for glutamine, alanine, serine, or threonine, fall in the range of ϳ10 -125 M MTX (unmeasurable for CPG2*(QAQ)). The corresponding surface-tethered enzymes have a narrower range of K m values, from 49 to 69 M MTX. Similarly, whereas the cytosolic proteins have catalytic values that are from 78% to Ͻ1% (unmeasurable for CPG2*(QAQ)) of the activity of CPG2*, the surface-tethered proteins have activities in a much more restricted range, from 29% to 40% of the activity of CPG2*. Thus, the surface-tethering process appears to ameliorate the effects of the mutations at the 264 position, most obvious with the alanine substitution.
One potential disadvantage of the surface-tethered protein is a generally higher K m for substrate compared with some of the internally expressed proteins. Thus, CPG2* and CPG2*(Q)3 have K m values of 7-10 M MTX, whereas all of the surface-tethered proteins have K m values that are 4-to 6-fold higher. In the presence of excess substrate, this would have little consequence, and in an antibody-directed enzyme prodrug therapy trial, peak CMDA concentrations of ϳ3 mM have been measured in the sera of patients, 27 demonstrating that high plasma concentrations can be achieved. We are currently unable to explain the molecular basis of the membrane-mediated activity enhancement, but it could be that by restricting the protein to the outer surface of the cell membrane, dimerization is facilitated due to local increases in protein concentration. In immunofluorescent studies, we observed stCPG2(Q)3 associated with membrane structures that resemble ruffles, 21 suggesting that local concentration effects may occur.
None of the other amino acid substitutions in the surface-tethered context offer any significant advantages over stCPG2(Q)3. Ultimately, the stCPG2(Q)3 protein is shown to be highly active, with a catalytic value that is ϳ40% of that of the wild-type protein. Nevertheless, we consistently observed levels of activity in the stCPG2(Q)3-expressing clones that were significantly lower than the 40% expected when compared with corresponding CPG2*-expressing cells. This is most obvious with the SK-OV-3 cells, where the stCPG2(Q)3-expressing clones express only ϳ2% of the CPG2 activity of corresponding CPG2*-expressing cells, yet give similar cytotoxicity and bystander effects. Even with WiDr cells, which had the least difference, the stCPG2(Q)3 clones only express ϳ10% of the activity of the CPG2*-expressing cells. This suggests that the stCPG2(Q)3 protein cannot be expressed at, or accumulate to, the high levels that can be achieved by CPG2*. Despite this, in a range of cell lines, cells expressing stCPG2(Q)3 have similar sensitivities to CMDA compared with cells expressing CPG2*. We show that lower levels of enzyme activity at the cell surface give levels of cell kill that can only be achieved by higher levels of activity of cytosolic protein. Similarly, low levels of enzyme activity at the cell surface mount a bystander effect that can only be achieved by higher levels of cytosolic enzyme. Finally, we observe that relatively short exposures to prodrug are effective at mediating cell killing for surface expression, whereas higher concentrations of enzyme activity and longer prodrug treatments are required with intracellularly expressed enzyme. Thus, despite the apparently unfavorable kinetics and low expression levels, stCPG2(Q)3 offers significant advantages to cell kill, and these advantages apply to a range of tumor cell lines.
Not all enzyme/prodrug systems will be suitable for the surface-tethering approach. Nitroreductase, 9 which relies on the cellular cosubstrates reduced nicotinamide-adenine dinucleotide and reduced nicotinamide-adenine dinucleotide phosphate, is unlikely to be suitable, as the enzyme will be inactive on the cell surface unless a suitable cosubstrate can be provided. Similarly, thymidine kinase, 9 which produces toxic phosphorylated compounds that are impermeable to the cell membranes, is unlikely to work, as the activated drugs will not enter the cells. However, enzymes that do not need cofactors and do not generate charged intermediate species are likely to function if surface tethered, and so this approach is likely to be of wide general utility. Nor does the approach require a monomeric enzyme, because CPG2 is active as a dimer. Where possible, external activation of prodrug is always likely to be advantageous. Because the prodrug does not have to enter the cell, its interaction with its activating enzyme and hence drug formation are likely to be more efficient, leading to rapid prodrug cleavage and relatively short prodrug exposure times for efficient cell killing. In the dynamic situation of a patient, where prodrug is likely to be cleared quickly from the body, rapid prodrug activation may be a distinct advantage over systems that require the prodrug first to enter cells to be activated. The pharmacokinetics of CMDA are relatively rapid, and in an antibody-directed enzyme prodrug therapy clinical trial, elimination of CMDA was monophasic, with a half-life of 25-35 minutes. 28 Further advantage can be obtained if the activated drug is relatively lipophilic, as is the case here, because it will partition into membranes rapidly and so will be less likely to be washed away from the tumor site. Activa-tion of the prodrug outside the cell is also likely to favor the bystander effect, because once the drug is activated, it will not have to leave the activating cell to enter the neighboring cells to result in bystander killing.
Expression of enzymes at the tumor cell surface also permits the design of alternative classes of prodrugs for GDEPT protocols. Intracellular expression of an activating enzyme requires that the prodrugs are cell permeable, but they will then be absorbed potentially by all the cells of the body, requiring substantial prodrug dose administration to maintain circulating levels at effective doses. Also, because cell entry is a requirement, the potential for activation at low levels by endogenous cytosolic enzymes with overlapping substrate specificities could lead to unacceptable levels of systemic toxicity. These problems can be circumvented with prodrugs that are impermeable to the cell membrane. It is desirable that these prodrugs release cell-permeable drugs to facilitate drug uptake by the targeted cells. This strategy should facilitate bystander effects in vivo that are independent of cell-to-cell communication mechanisms such as gap junctions, which are absent in many tumor cells. 29 Thus, cell surface expression of an activating enzyme represents a powerful potential general method for sensitizing cells to prodrugs and an improvement in activating enzyme technology for GDEPT approaches.
Previously, it was shown that surface tethering overcomes the problem of poor intracellular access of prodrug in the very resistant human breast adenocarcinoma cell line MDA MB 361. However, in that study, we were unable to compare the efficacy of this approach with intracellular enzyme because of the failure of CPG2* to sensitize these cells to CMDA. 21 This is the first time that these two systems have been compared directly, using cells that can be sensitized by both. In all cell lines, expression of small amounts of stCPG2(Q)3 activity at the cell surface leads to cytotoxicity and to bystander effects that are very similar to those generated by high levels of expression of fully active CPG2*. In addition, for the resistant WiDr and SK-OV-3 cell lines, the speed of intoxication is much more rapid. One cell type, the highly sensitive A2780 cell line, appears equally sensitive to short CMDA treatments regardless of whether CPG2* or stCPG2(Q)3 is expressed, and so stCPG2(Q)3 may offer no particular advantage for these types of tumors. Nevertheless, even in this example, stCPG2(Q)3-mediated CMDA cleavage is at least as good as that provided by CPG2*, so surface tethering shows a more widespread general utility. We have shown here that maximal enzyme activity is not a good indicator of cytotoxicity for GDEPT approaches, but that the site of expression of the enzyme is of major importance. Cell surface tethering can result in much greater efficiency, despite unfavorable kinetics and expression levels. The data presented here define many of the important parameters for these types of emerging approaches.
